Track topics on Twitter Track topics that are important to you
– Positive top-line PROMISE 1 study results further support eptinezumab’s unique clinical profile –
– $161.5 million from recent public offering expected to enable continued advancement of eptinezumab through pivotal studies, a planned Biologics License Application and achievement of other key activities –
– Conference call set for 5 p.m. EDT today –
BOTHELL, Wash., Aug. 08, 2017 (GLOBE NEWSWIRE)NEXT ARTICLE
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...